Educational research on US and Indian equities, ETFs, mutual funds and crypto, with screeners and a free investing academy.
All data is for educational purposes only and should not be considered investment advice.
Equiscale is operated by Syntellia LLC, a Delaware limited liability company.
© 2026 Syntellia LLC. All rights reserved.
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 5 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $883M | $207M | $78M | $151M | 14.5% | 43.8% | -522.9% |
| 2024 | $614M | $63M | $-19M | $47M | -4.6% | 26.2% | -198.6% |
| 2023 | $487M | $107M | $19M | $100M | 4.3% | 53.9% | -139.2% |
| 2022 | $316M | $25M | $-48M | $-48M | -15.3% | - | - |
| 2021 | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2025 |
|---|---|
| Total Revenue | 883.37 |
| Operating Revenue | 883.37 |
| Cost Of Revenue | 341.31 |
| Gross Profit | 542.06 |
| Operating Expense | 460.83 |
| Research And Development | 51.66 |
| Selling General And Administration | 317.74 |
| Total Expenses | 802.14 |
| Operating Income | 81.23 |
| Total Operating Income As Reported | 111.09 |
| EBITDA | 207.27 |
| Normalized EBITDA | 174.58 |
| EBIT | 115.85 |
| Interest Expense | 20.06 |
| Net Interest Income | -20.06 |
| Other Non Operating Income Expenses | 1.93 |
| Other Income Expense | 34.62 |
| Interest Expense Non Operating | 20.06 |
| Net Non Operating Interest Income Expense | -20.06 |
| Pretax Income | 95.79 |
| Tax Provision | 17.45 |
| Tax Rate For Calcs | 0 |
| Tax Effect Of Unusual Items | 5.95 |
| Net Income Continuous Operations | 78.34 |
| Net Income From Continuing And Discontinued Operation | 78.34 |
| Net Income From Continuing Operation Net Minority Interest | 78.34 |
| Net Income | 78.34 |
| Net Income Common Stockholders | 70.22 |
| Net Income Including Noncontrolling Interests | 78.34 |
| Normalized Income | 51.60 |
| Diluted NI Availto Com Stockholders | 70.57 |
| Basic Average Shares | 20.05 |
| Diluted Average Shares | 21.23 |
| Reconciled Depreciation | 91.42 |
| Reconciled Cost Of Revenue | 341.31 |
| Total Unusual Items | 32.69 |
| Total Unusual Items Excluding Goodwill | 32.69 |
| Preferred Stock Dividends | 1.16 |
| Special Income Charges | 29.86 |
| Other Special Charges | - |
| Impairment Of Capital Assets | 0.77 |
| Restructuring And Mergern Acquisition | -31.01 |
| Gain On Sale Of Security | 2.82 |
| Depreciation Amortization Depletion Income Statement | 91.42 |
| Depreciation And Amortization In Income Statement | 91.42 |
| Gain On Sale Of Ppe | -0.38 |
| Other Operating Expenses | - |
| Otherunder Preferred Stock Dividend | 6.96 |
| Average Dilution Earnings | 0.35 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| ANI Pharmaceuticals, Inc.this co. | ANIP | $1.8B | 22.99 | 3.33 | 14.5% | 10.29 |
| Maravai LifeSciences Holdings, Inc. | MRVI | $1.8B | -14.08 | 8.67 | -61.6% | -13.48 |
| Pediatrix Medical Group, Inc. | MD | $1.8B | 11.11 | 2.12 | 19.1% | 7.64 |
| Viridian Therapeutics, Inc. | VRDN | $1.8B | -5.34 | 3.10 | -58.1% | -4.95 |
| Vericel Corporation | VCEL |
| - |
| - |
| - |
| - |
| - |
| - |
| $1.8B |
| 110.33 |
| 5.14 |
| 4.7% |
| 60.29 |
| Nuvation Bio Inc. | NUVB | $1.8B | -8.80 | 5.89 | -66.9% | -8.95 |
| Rapport Therapeutics, Inc. | RAPP | $1.8B | - | -178.20 | -23.0% | - |
| Surgery Partners, Inc. | SGRY | $1.8B | -22.97 | 1.04 | -4.5% | 9.86 |
| SELLAS Life Sciences Group, Inc. | SLS | $1.8B | -66.17 | 25.08 | -37.9% | -60.37 |
| Peer Median | - | -8.80 | 4.12 | -30.5% | -4.95 | |